Progressive intellectual decline acquired in late life constitutes a major challenge to public health, in terms both of the medical and community services required to support an intellectually and physically frail population, and the physical and emotional strain on patients and their carers. Although the first scientific breakthrough occurred 80 years ago, with Alzheimer's description, using a new silver staining technique,' of characteristic neuropathological changes in dementia, it is in the last two decades that there has been a resurgence of research interest, with major advances in the neurochemistry, histopathology and molecular biology of the disorder.
Definition and causes of dementia
Dementia may be defined as an acquired, multidimensional cognitive decline, occurring in the absence of clouding of consciousness, which distinguishes it from confusional states due to metabolic, infective or other insults. The intellectual decline is required to be sufficient to interfere with normal social functioning,2 and the stipulation that it is acquired distinguishes it from developmental retardation. Using such a definition, the reported annual incidence rates vary between 0.3 and 2.5% of the population aged 65 years or over. 3 The magnitude of the problem will clearly increase in parallel with the predicted increase in the number of elderly people.
Any condition in which there is widespread disruption of normal neuronal architecture within the cerebral cortex, particularly if there is disruption of cortico-cortical association tracts, would be expected to cause dementia. The commonest causes are Alzheimer's disease (AD), and multi-infarct dementia, although other conditions should be considered, (Table I) , particularly in younger patients, or those with atypical features.
A precise diagnosis of the cause of dementia in a given patient is often not achieved, so a clinical classification can be more helpful than an aetiological one. A clinical distinction between cortical and subcortical dementias has been proposed,4 on the basis of the type of intellectual deterioration in progressive supranuclear palsy and Huntington's disease (Table II) . The absence of aphasia, apraxia and agnosia in these diseases was contrasted with the cortical dementias, as exemplified by Alzheimer's disease.
This article will deal initially with Alzheimer's disease, the commonest and most intensively studied of the dementias, and will then consider other causes.
Alzheimer's disease (AD) Alzheimer1 described a patient with severe progressive memory loss, dysphasia, and dyslexia, in whom the new silver staining method allowed the first demonstration of the neurofibrillary tangles, that together with senile plaques, are considered diagnostic of the disease. Sixty years later, this technique was used to demonstrate a quantitative relationship between the plaque count post-mortem, and the severity of the dementia.5 A significant association between clinical severity and neurofibrillary tangle (NFT) count has also been recently described. 6 The presence of both these histopathological abnormalities in AD implies a disruption of neuronal circuitry, either as a cause or a consequence of the cellular changes.
Classically, neuropsychological deficits are related to the area of cortex damaged, for example, Broca's aphasia is a specific clinical syndrome associated with a dominant frontal lobe lesion. While such a 
Neurotransmitter changes in AD
Since the discovery of a cholinergic deficit in AD, 2' there has been a great deal of interest in the neurotransmitter changes in dementia, although the initial hope for a treatable deficit -analogous to the dopaminergic deficit in Parkinson's diseasehas not been realised. The relationship between the structural changes of neuronal loss, NFTs, neuritic plaques and neurochemical markers has been studied, allowing some insight into the biochemical selectivity of the diseased neuronal networks.
A reduction in the activity of the enzyme choline acetyl-transferase (ChAT) in selected brain regions in AD was first described in 1976.21 Since this biosynthetic enzyme is confined to acetylcholine neurones, it is a valuable marker of the cholinergic system. Reduced ChAT activity is reported in all areas of neocortex, particularly temporal cortex and hippocampus, but not all subcortical areas.22 The
ChAT activity has been correlated with both the density of senile plaques and NFTs, and with the severity of dementia. More specifically, a recent biopsy study revealed a correlation between the severity of dementia, and the degree of pathological change in large cortical neurones, and with a reduction in acetylcholine synthesis.23
Muscarinic cholinergic receptors are the predominant cholinergic receptors in the central nervous system, and the subtype M2, which is believed to be presynaptic, is reported to be selectively lost in AD.24 This is confirmed in vivo by single photon emission tomography studies which show impaired muscarinic binding using iodine labelled QNB (3-quinuclidinyl-4-iodobenzilate, a muscarinic antagonist).25 Relative preservation of post-synaptic (Ml) receptors is an important observation since intact post-synaptic receptors would be necessary for cholinergic therapy. By contrast, significant reduction in nicotinic binding in AD is found in frontal, temporal and occipital cortex,26 although the role of nicotine in cognition is unknown. The association of cholinergic cell loss with AD suggests that the ascending projections from the basal forebrain to the neocortex and hippocampus are associated with memory and other aspects of cognitive function. This view is supported by pharmacological studies that demonstrate impairment of memory and attention by cholinergic blockade.7 However, although the cholinergic abnormality is a major feature of AD, this is now seen within the context of a variety of neurotransmitter deficits (Table III) .
Other ascending projections from the brain stem, namely noradrenergic and serotonergic, are involved, and loss of the chemical marker in the central nervous system can be related to loss of cells from the nucleus of origin. However, none of these changes can be related to the intrinsic cortical pathology of cell loss and NFT formation. A number of neurotransmitters are used by cortical cells, and the major inhibitory system, gamma amino butyric acid (GABA), is involved in AD. Some GABA cells also contain neuropeptides (see Table III ), which may explain the loss of somatostatin which is a consistent feature of AD. signs. Both neurochemical changes and neuropathology vary according to age. It has been suggested that AD may thus represent more than one disease, similar to the older distinction between senile and presenile cases or it might be seen as a spectrum of disorder. Careful definition of clinical subgroups, with post-mortem correlation, will be necessary to clarify the nosology of the disorder.
Biochemical studies on post-mortem tissue have provided valuable information on the nature of neurotransmitter deficits. However, there are clear disadvantages to post-mortem biochemistry, as the studies are usually of end stage disease. Biopsy studies allow analysis of fresh material earlier in the disease process, but there are considerable practical and ethical difficulties in obtaining cortical biopsies from demented patients. In vivo studies of biochemical markers are now possible using positron emission tomography, allowing visualization of at least some neurotransmitter systems non-invasively. Correlation of clinical features with in vivo biochemistry should give some insight into the biochemical nature of clinical subgroups, and thus direct possible future therapies. Attempts have been made to treat AD on the basis of the neurochemical deficits described, but treatment with precursor substrate loading with choline has been largely unsuccessful.63 One study showed some improvement in a subgroup of patients who had inhibition of cerebrospinal fluid cholinesterase while on treatment.64 A recent study using tetrahydroaminoacridine (THA),65 a centrally acting cholinesterase inhibitor, demonstrated significant improvements in some patients, although this is currently being assessed in a larger study. However, in view of the complexity of neurotransmitter abnormalities in AD, it would appear unlikely that simple cholinergic replacement would be of value, except perhaps in a subgroup of patients with a primarily cholinergic deficit. Neurotransmitter replacement would be most likely to be of value in those conditions such as the subcortical dementias, where a specific pathway is damaged. It is less likely to be of value in situations of massive neuronal loss.
In summary, the dementias are an ill understood group of disorders of differing aetiology and pathogenesis. Whilst rare disorders may be due to a single enzyme defect (e.g. metachromatic leucodystrophy), the aetiology of the commonest disorder, Alzheimer's disease, is unknown and probably multi-factorial. The final common pathway is disruption of neuronal connections in the cerebral cortex; some dementias are reversible, implying disruption at a metabolic level, while neuronal loss or damage to neuronal processes is largely irreversible. It is hoped that improved understanding of the pathophysiology will identify patients at the early, reversible stage.
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